Search | Clinical Trials Finder

Conditions: Women's Health, HIV Infection, Genital Diseases, Female
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: ART Adherence
Interventions: TXTXT, e-Navigation, Ecological Momentary Assessment (EMA) supported e-Navigation.; Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: Calanolide A; Drug
Lead sponsor: Sarawak MediChem Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 7
States / cities: Miami, Florida • Chicago, Illinois • Philadelphia, Pennsylvania + 3 more

Conditions: HIV Infections
Interventions: MRKAd5 HIV-1 gag/pol/nef, MRKAd5 HIV-1 gag/pol/nef placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 13
States / cities: San Diego, California • San Francisco, California • Torrance, California + 7 more

Conditions: HIV Infections
Interventions: Pegylated Interferon-alpha 2a, 180 mcg/week sc, Pegylated Interferon-alpha 2a, 90 mcg/week sc; Drug
Lead sponsor: The Wistar Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Philadelphia, Pennsylvania

Conditions: HIV, HIV/AIDS
Interventions: Peg-IFN-α2b; Drug
Lead sponsor: The Wistar Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: HIV-1-infection
Interventions: TMB-365/TMB-380; Drug
Lead sponsor: TaiMed Biologics Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: San Francisco, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 3 more

Conditions: HIV Infections
Interventions: YouTHrive, Information-only Control; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 15 Years to 24 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 7
States / cities: Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: HIV Infections
Interventions: tocilizumab, Placebo; Drug
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV Infections
Interventions: Pneumococcal 7-valent conjugate vaccine, Pneumococcal polysaccharide vaccine, Hepatitis B vaccine, Measles, mumps, and rubella virus vaccine, live; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years to 23 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 24
States / cities: Birmingham, Alabama • Alhambra, California • Long Beach, California + 17 more

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions: Vesatolimod, Cobicistat, Voriconazole, Rifabutin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Long Beach, California • Miami, Florida • West Palm Beach, Florida + 1 more

Conditions: HIV Infections
Interventions: Dolutegravir, Emtricitabine/tenofovir alafenamide, Emtricitabine/tenofovir disoproxil fumarate, Efavirenz/emtricitabine/tenofovir disoproxil fumarate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Jacksonville, Florida • Miami, Florida

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1349572, efavirenz; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 13
States / cities: Phoenix, Arizona • Bakersfield, California • Long Beach, California + 8 more

Conditions: HIV
Interventions: Mindfulness-Based Stress Reduction (MBSR), HIV-education and self-management workshop; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Los Angeles, California • Menlo Park, California • San Diego, California + 15 more

Conditions: Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy
Interventions: TLC-ART; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: HIV-1
Interventions: CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 24
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 19 more

Conditions: HIV
Interventions: Etravirine pharmacokinetics in breast milk and plasma; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HIV Infections
Interventions: Early Initiation of Highly Active Anti-Retroviral Therapy, Standard Care; Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 24 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 22
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 17
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 12 more

Conditions: Depressive Symptoms, HIV Infections
Interventions: Cognitive-Behavioral Therapy (CBT-AD); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: HIV Infections
Interventions: MPC-4326 plus a 2-3 drug optimized background regimen (OBR), 3-4 commercially available antiretroviral drugs; Drug
Lead sponsor: Myrexis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 21
States / cities: Beverly Hills, California • Los Angeles, California • San Francisco, California + 16 more

Conditions: HIV Infections
Interventions: ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 18 more

Conditions: HIV Infections
Interventions: VRC01, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 13
States / cities: San Diego, California • Aurora, Colorado • Chicago, Illinois + 10 more

Search by objective public record fields.

Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract

Efficacy of mHealth + e-Navigator Stepped Care Intervention for ART Adherence Among Latino Men With HIV

The Safety and Effectiveness of (+)-Calanolide A in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection

Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection

Reducing Proviral HIV DNA With Interferon-a

TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals

Connecting Youth and Young Adults to Optimize ART Adherence: YouTHrive Efficacy Trial

AIDS 347: IL-6 Blockade in Treated HIV Infection

Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs

Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels

Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

Staying Well: A Clinical Trial of Mindfulness-Based Stress Reduction and Education Groups for HIV

A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV Therapy

First in Human Study of TLC-ART 101 (ACTU 2001)

Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma

Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)

A Study of Two Methods of Determining When to Begin or Change Anti-HIV Treatment

Depression and ART Adherence in HIV+ Latinos

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination

Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)